El Mundo on MSN
The revolution of the 'Ozempic' drugs and the challenges of a solution for almost everything: "We are facing massive use"
A review by researchers from the Cochrane publication focuses on the new 'superdrugs': questioning the rebound effect, ...
Medicare coverage will cut obesity-drug prices but open the door to millions of new patients.
The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback